BMS Enters the Biologics Acquisition Game
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 89 (Table of Contents)
Published: 1 Nov-2007
DOI: 10.3833/pdr.v2007.i89.260 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
The increasing focus on biologics that has gripped big pharma was recently demonstrated in the US$430 M acquisition of Adnexus Therapeutics by Bristol-Myers Squibb (BMS)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018